Zoetis (ZTS) Posts Quarterly Earnings Results

Zoetis (NYSE:ZTS) issued its earnings results on Thursday. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.66 by $0.03, Bloomberg Earnings reports. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.47 EPS. Zoetis updated its FY18 guidance to $2.96-3.10 EPS.

Zoetis (NYSE:ZTS) opened at $78.71 on Thursday. The firm has a market cap of $35,688.99, a price-to-earnings ratio of 39.19, a P/E/G ratio of 1.62 and a beta of 1.07. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a one year low of $52.00 and a one year high of $80.60.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be paid a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s payout ratio is presently 26.32%.

Several equities analysts have recently issued reports on the stock. BMO Capital Markets set a $78.00 price target on shares of Zoetis and gave the company a “hold” rating in a report on Monday, January 22nd. Piper Jaffray Companies reissued a “buy” rating and issued a $86.00 price target on shares of Zoetis in a report on Thursday, January 18th. Jefferies Group reissued a “buy” rating and issued a $89.00 price target on shares of Zoetis in a report on Tuesday, January 16th. Zacks Investment Research lowered shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 price target for the company. in a report on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Thursday, January 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $73.72.

A number of hedge funds and other institutional investors have recently made changes to their positions in ZTS. Shelton Capital Management acquired a new position in shares of Zoetis during the 2nd quarter worth about $232,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Zoetis during the 2nd quarter worth about $917,000. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Zoetis by 51.4% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 31,041 shares of the company’s stock worth $1,936,000 after buying an additional 10,539 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its stake in shares of Zoetis by 7.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock worth $368,000 after buying an additional 401 shares during the last quarter. Finally, Advisory Services Network LLC boosted its stake in shares of Zoetis by 82.4% during the 2nd quarter. Advisory Services Network LLC now owns 3,829 shares of the company’s stock worth $239,000 after buying an additional 1,730 shares during the last quarter. 93.72% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/15/zoetis-zts-posts-quarterly-earnings-results.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Earnings History for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply